Open Journal of Rheumatology and Autoimmune Diseases
Vol.6 No.4(2016), Paper ID 72137, 14
pages
DOI:10.4236/ojra.2016.64017
Iguratimod, a Disease-Modifying Anti-Rheumatic Drug, Inhibits Osteoclastogenesis and Bone Resorption through Suppression of the Nuclear Factor of Activated T Cells Signaling Pathway
Jun Shiota, Hidetoshi Murao, Akihiko Miura, Masaaki Mikami, Keiichi Tanaka
Research Laboratories, Toyama Chemical Co., Ltd., Toyama, Japan
Research Laboratories, Toyama Chemical Co., Ltd., Toyama, Japan
Research Laboratories, Toyama Chemical Co., Ltd., Toyama, Japan
Research Laboratories, Toyama Chemical Co., Ltd., Toyama, Japan
Research Laboratories, Toyama Chemical Co., Ltd., Toyama, Japan
Copyright © 2016 Jun Shiota, Hidetoshi Murao, Akihiko Miura, Masaaki Mikami, Keiichi Tanaka et al. This is
an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
How to Cite this Article
Shiota, J. , Murao, H. , Miura, A. , Mikami, M. and Tanaka, K. (2016) Iguratimod, a Disease-Modifying Anti-Rheumatic Drug, Inhibits Osteoclastogenesis and Bone Resorption through Suppression of the Nuclear Factor of Activated T Cells Signaling Pathway.
Open Journal of Rheumatology and Autoimmune Diseases,
6, 106-119. doi:
10.4236/ojra.2016.64017.